ClinicalTrials.gg
Active, not recruitingNCT03573401Updated Jan 14, 2026Results posted

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

A Phase 3 interventional study of Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) and Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) in Superficial Basal Cell Carcinoma, sponsored by Biofrontera Inc.. Active, not recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Biofrontera Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
15th of 139
187 · median 40
Started
2018
with 5 others
Phase 3
7 of 171
1 open now
Primary completion
2024-03
later than 3 of 37 live
Registered
100th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 15th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2018, is one of 7 in phase 3, reaches primary completion later than 3 of the 37 other live ones, and was the 100th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).

Read the detailed description

The study will be conducted as randomized, double blind and vehicle-controlled ( 4:1 ratio of verum (BF-200 ALA; Ameluz®) to vehicle (placebo)) clinical trial at 15 sites in the United States of America (US). Each site should randomize between 10 and 20 subjects.

Each subject will complete a clinical observation period that will last for up to 7 months (up to 4 weeks screening and pre-randomization period, and up to 6 months clinical observation period) followed by a 5-year follow-up (FU) period after the completion of the first PDT cycle.

The treatment of superficial BCC lesion(s) comprises of up to two PDT cycles each with two PDT sessions one to two weeks apart of each other. 12 weeks after the first PDT of the first cycle lesion(s) will be assessed clinically and only subjects with remaining BCC lesion(s) will be retreated in the second PDT cycle starting the same day. For clinically completely cleared subjects the clinical observation period of the study will end and these subjects will enter the FU part of the study.

For each subject a Main Target Lesion will be defined that will be excised either 12 weeks after the first PDT of the first cycle, if clinically cleared, or at the end of the clinical observation period in order to histologically confirm the clinical assessment. Additional Target Lesions will be assessed clinically, only. Randomization will be stratified by the number of lesions (1 vs ≥2 Lesion(s)).

Definitions of complete responders comprise of:

  1. Complete response of the Main Target Lesion which is assessed 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion and is defined as a Main Target Lesion that is completely clinically and histologically cleared.
  2. In general, clinically complete responders are categorized 12 weeks after the start of the last PDT cycle according to clinical assessment only and are defined as subjects with all lesions (Main plus Additional Target Lesions) clinically cleared.

Verum and vehicle are indistinguishable. However, treatment is accompanied with typical adverse events (AEs). In order to guarantee the blind status of the investigator assessing efficacy after each PDT cycle, a second investigator or delegated person will perform drug application and light treatment as well as all safety evaluations at visits where PDT is applied and during the phone call 1 week after each PDT cycle, respectively. Both investigators (delegated person(s)) are not entitled to exchange information about the study outcome and side effects.

03

Conditions studied

  • Superficial Basal Cell Carcinoma

Browse trials for

Keywords

  • ALA-PDT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness and ability to sign the form and Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent form and a HIPAA form must be obtained in writing for all subjects prior to starting any study procedures.
  • Men or women ≥18 years of age.
  • Presence of ≥1 naïve sBCC lesion in the treatment areas face/forehead, bald scalp, extremities and/or neck/trunk, all of which are, according to the clinical judgement of the investigator, likely to be confirmed as sBCCs. Lesions should not be within the embryonic fusion planes (H-zone), especially within 2 cm of the hair zone or on the ears. In case of multiple lesions, one lesion is defined as Main Target Lesion which will be excised at the end of the clinical observation period. Only eligible naïve sBCCs, confirmed by histology taken at screening, are allowed to be included in the study as Main or Additional Target Lesions. Thus, eligible sBCCs must lack any histological evidence of aggressive growth patterns (e.g. severe squamous metaplasia, infiltrative/desmoplastic features or basosquamous features). BCCs assessed as non-naïve (e.g. previously treated or recurrent) or non-eligible by taken at screening (and in a distance >5 cm from the next lesion included in the study) should be excised by surgery or removed by cryotherapy in a timely manner. Other treatments for these lesions are not allowed during the study.
  • The diameter of each eligible lesion should be ≥ 0.6 cm, and the entire treatment field must not exceed \~20 cm². The treatment field is defined as the field to which IMP is applied, usually including the target lesions and margins surrounding the lesions of up to 1 cm. For the Main Target Lesion, the maximal lesion size should be such that surgical excision without a skin transplant is feasible according to the investigator's judgement.
  • Target BCC lesions must be discrete and located within 1-2 illumination areas (the illumination area is defined by the effective illumination area of the BF-RhodoLED® device with approximately 6 x 16 cm).
  • Willingness to receive up to 4 PDTs within 3.5 months and excision of the Main Target Lesion either at Visit 5, if clinically cleared, or at the end of the clinical observation period 12 weeks after the start of the last PDT cycle (Visit 8), irrespective of whether the treated Main Target Lesion was clinically cleared or not.
  • Free of significant physical abnormalities (e.g. tattoos, dermatoses) within the potential treatment field plus a 5 cm radius surrounding the target lesion(s) as they may interfere with examination or final evaluation.
  • Willingness to stop the use of moisturizers and any other cosmetics within the treatment field plus a 5 cm radius surrounding the target lesion(s) 48 hours prior to an office visit and 48 hours after each PDT session. Sunscreen will be allowed, but should not be applied to the treatment field plus the 5 cm radius surrounding the target lesion(s) within approximately 24 h prior to a clinical visit.
  • Acceptance to abstain from extensive sunbathing and the use of a solarium during the clinical observation period. Subjects with sunburn within treatment areas cannot be included until fully recovered.
  • Healthy subjects and subjects with clinically stable medical conditions, including, but not limited to controlled hypertension, diabetes mellitus type II, hypercholesterolemia, and osteoarthritis, will be permitted to be included in the study if their medication is not prohibited by this protocol.
  • Women of are permitted to participate in this study only if they have a negative serum pregnancy test at screening and are willing to use a highly effective method of during the clinical observation period of the study.

Exclusion criteria

Exclusion Criteria:

  • History of to 5-ALA or any ingredient of BF-200 ALA which includes soybean phosphatidylcholine.
  • Hypersensitivity to porphyrins.
  • Current treatment with therapy.
  • Presence of photodermatoses.
  • Presence of porphyria.
  • Presence of inherited or acquired coagulation defect.
  • Evidence of clinically significant (CS) unstable medical conditions, such as:

    • tumor or tumor with high probability of metastasis.
    • Cardiovascular disease class III, IV ( [NYHA]).
    • Immunosuppressive condition.
    • Hematologic, hepatic, renal, neurologic, or endocrine condition.
    • Collagen-vascular condition.
    • Gastrointestinal condition.
  • Clinically relevant cardiovascular, hepatic, renal, neurologic, endocrine, or other major systemic diseases that complicate implementation of the protocol or interpretation of the study results.
  • Gorlin Syndrome or Xeroderma pigmentosum.
  • Presence and/or physical treatment of skin tumors other than (naïve) sBCC (e.g. malignant melanoma, squamous cell carcinoma (SCC), Bowen's disease, aggressive BCC or nBCC diagnosed at the screening visit by clinical assessment) within a distance of ≤ 5 cm from the nearest target lesion within 4 weeks prior to PDT (Visit 2) until the end of the clinical observation period. However, biopsied lesion(s) that were not confirmed eligible at screening and which are located at a distance of > 5 cm from any lesion(s) that will be included in the study can be surgically removed. Treatment by PDT or topical medication during the course of the clinical observation period of the study triggers exclusion of the subject.
  • If lesion(s) are assessed as non-eligible by during initial screening and these lesions are localized within a distance of 5 cm from an otherwise suitable lesion, this suitable lesion must be excluded from the study.
  • Αny AK lesions within the treatment field (lesion area including margin of 0.5 to 1.0 cm).
  • Any topical medical treatment of AK, other non-melanoma skin cancers (NMSC), or melanoma (except for IMP treatment of the target lesion(s)) starting 12 weeks prior to Visit 2 (PDT-1) and lasting until the end of the clinical observation period.
  • Any other topical medical treatment of the skin 12 weeks prior to Visit 2 (PDT-1) until the end of the clinical observation period, with the exception of:

    • Topical treatments with (allowed throughout the clinical observation period of the study).
    • Topical non-steroidal anti-inflammatory drugs (NSAIDs such as diclofenac) (allowed throughout the clinical observation period of the study with the restriction of 7 days prior to and 7 days after PDTs).
  • Start of intake of medication with hypericin or systemically acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening.
  • Any of the systemic treatments listed below, within the designated period prior to PDT and during the clinical observation period.

    • Interferon - 6 weeks
    • Immunomodulators or immunosuppressive therapies - 12 weeks
    • Cytotoxic drugs - 6 months
    • drugs - 8 weeks
    • Drugs known to have major organ toxicity - 8 weeks
    • Corticosteroids (oral or injectable) - 6 weeks
    • MAL or ALA - 12 weeks
  • Systemic treatment with NSAIDs is not to be used 7 days prior to and 7 days after PDT. ASA (e.g. Aspirin®) up to 100 mg/ day, ibuprofen up to 200 mg/ day, and acetaminophen (e.g. Tylenol®) is allowed during this period.
  • Presence of tattoos, skin inflammation, wounds, etc. in the treatment field(s) plus a 5 cm radius surrounding the target lesion(s).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    BF-200 ALA

    Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid). Photodynamic therapy (PDT)

    Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

  • Placebo comparator
    Vehicle

    Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)

    Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

Interventions

  • Combination productPhotodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

    The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.

    Also known as: ALA-PDT, Ameluz®-PDT

  • Combination productPlacebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

    The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.

06

What researchers measure

Primary outcomes

  1. Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion.

    Each subject had one Main Target Lesion. The composite clinical and histological response rate of the subjects' Main Target Lesions is the percentage of subjects with a clinically and histologically cleared Main Target lesion 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion (Visit 5 or Visit 8).

    Time frame: 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion

Secondary outcomes

  1. Main Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle

    1\. Key secondary endpoint: Percentage of Main Target Lesions with complete clinical clearance (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle.

    Time frame: 12 weeks after the start of the last PDT cycle

  2. Main Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle

    2\. Key secondary endpoint: Percentage of Main Target Lesions with complete histological clearance (i.e. according to histological assessment only) 12 weeks after the start of the last PDT cycle.

    Time frame: 12 weeks after the start of the last PDT cycle

  3. Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle.

    3\. Key secondary endpoint: Percentage of subjects with complete clinical clearance of all Target Lesions (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle.

    Time frame: 12 weeks after the start of the last PDT cycle

  4. Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle.

    4\. Key secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of all Additional Target Lesions 12 weeks after the start of the last PDT cycle

    Time frame: 12 weeks after the start of the last PDT cycle

  5. Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle.

    Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after the start of the last PDT cycle.

    Time frame: 12 weeks after the start of the last PDT cycle

  6. Main Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1.

    Further secondary endpoint: Percentage of Main Target Lesions that are clinically and histologically cleared 12 weeks after PDT-1.

    Time frame: 12 weeks after PDT-1

  7. Main Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.

    Further secondary endpoint: Percentage of Main Target Lesions that are clinically cleared 12 weeks after PDT-1.

    Time frame: 12 weeks after PDT-1

  8. Main Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1.

    Further secondary endpoint: Percentage of Main Target Lesions that are histologically cleared 12 weeks after PDT-1.

    Time frame: 12 weeks after PDT-1

  9. Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1.

    Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after PDT-1

    Time frame: 12 weeks after PDT-1

  10. Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.

    Further secondary endpoint: Percentage of subjects with complete clinical clearance 12 weeks after PDT-1.

    Time frame: 12 weeks after PDT-1

  11. Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1..

    Further secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of Additional Target Lesions 12 weeks after PDT-1.

    Time frame: 12 weeks after PDT-1

  12. For All Target Lesions, Assessment of Esthetic Appearance by the Investigator 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion and Any Alternative Treatment of Additional Target Lesions.

    Further secondary endpoint: Investigators assessment of the esthetic appearance of all Target lesions but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions

    Time frame: 12 weeks after the start of the last PDT cycle

  13. Subjects' Satisfaction Regarding Esthetic Outcome and Treatment 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion or Alternative Treatment of Additional Target Lesions

    Further secondary endpoint: Subject's assessment regarding the esthetic outcome and the Treatment 12 weeeks after the start of the last PDT cycle but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions

    Time frame: 12 weeks after the start of the last PDT cycle

07

Results

Posted Apr 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneBF-200 ALAVehicle
Started14542
Completed14141
Not completed41
Withdrew: Withdrawal by subject20
Withdrew: Subject non-compliance with study schedule10
Withdrew: Discontinuation of study treatment due to subject decision10
Withdrew: Subject required prohibited medication for concomitant medical condition01

Outcome measures

PrimaryComposite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion.

Each subject had one Main Target Lesion. The composite clinical and histological response rate of the subjects' Main Target Lesions is the percentage of subjects with a clinically and histologically cleared Main Target lesion 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion (Visit 5 or Visit 8).

Time frame:
12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion
Reported as:
Number · percentage of subjects
Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion.
percentage of subjectsBF-200 ALAVehicle
Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion.65.54.8
SecondaryMain Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle

1\. Key secondary endpoint: Percentage of Main Target Lesions with complete clinical clearance (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle.

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of Main Target Lesions
Main Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle
percentage of Main Target LesionsBF-200 ALAVehicle
Main Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle83.421.4
SecondaryMain Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle

2\. Key secondary endpoint: Percentage of Main Target Lesions with complete histological clearance (i.e. according to histological assessment only) 12 weeks after the start of the last PDT cycle.

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of Main Target Lesions
Main Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle
percentage of Main Target LesionsBF-200 ALAVehicle
Main Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle75.919.0
SecondarySubject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle.

3\. Key secondary endpoint: Percentage of subjects with complete clinical clearance of all Target Lesions (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle.

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of subjects
Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle.
percentage of subjectsBF-200 ALAVehicle
Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle.82.121.4
SecondarySubject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle.

4\. Key secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of all Additional Target Lesions 12 weeks after the start of the last PDT cycle

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of subjects
Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle.
percentage of subjectsBF-200 ALAVehicle
Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle.64.14.8
SecondaryLesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle.

Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after the start of the last PDT cycle.

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of target lesions
Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle.
percentage of target lesionsBF-200 ALAVehicle
Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle.82.621.6
SecondaryMain Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1.

Further secondary endpoint: Percentage of Main Target Lesions that are clinically and histologically cleared 12 weeks after PDT-1.

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of Main Target Lesions
Main Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1.
percentage of Main Target LesionsBF-200 ALAVehicle
Main Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1.44.12.4
SecondaryMain Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.

Further secondary endpoint: Percentage of Main Target Lesions that are clinically cleared 12 weeks after PDT-1.

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of Main Target Lesions
Main Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.
percentage of Main Target LesionsBF-200 ALAVehicle
Main Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.57.214.3
SecondaryMain Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1.

Further secondary endpoint: Percentage of Main Target Lesions that are histologically cleared 12 weeks after PDT-1.

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of Main Target Lesions
Main Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1.
percentage of Main Target LesionsBF-200 ALAVehicle
Main Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1.44.82.4
SecondaryLesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1.

Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after PDT-1

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of target lesions
Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1.
percentage of target lesionsBF-200 ALAVehicle
Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1.58.713.7
SecondarySubject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.

Further secondary endpoint: Percentage of subjects with complete clinical clearance 12 weeks after PDT-1.

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of subjects
Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.
percentage of subjectsBF-200 ALAVehicle
Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1.54.514.3
SecondarySubject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1..

Further secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of Additional Target Lesions 12 weeks after PDT-1.

Time frame:
12 weeks after PDT-1
Reported as:
Number · percentage of subjects
Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1..
percentage of subjectsBF-200 ALAVehicle
Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1..41.42.4
SecondaryFor All Target Lesions, Assessment of Esthetic Appearance by the Investigator 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion and Any Alternative Treatment of Additional Target Lesions.

Further secondary endpoint: Investigators assessment of the esthetic appearance of all Target lesions but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of target lesions
For All Target Lesions, Assessment of Esthetic Appearance by the Investigator 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion and Any Alternative Treatment of Additional Target Lesions.
percentage of target lesionsBF-200 ALAVehicle
Very good61.934.0
Good27.424.0
Satisfactory9.528.0
Unsatisfactory0.610.0
No answer0.64.0
SecondarySubjects' Satisfaction Regarding Esthetic Outcome and Treatment 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion or Alternative Treatment of Additional Target Lesions

Further secondary endpoint: Subject's assessment regarding the esthetic outcome and the Treatment 12 weeeks after the start of the last PDT cycle but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions

Time frame:
12 weeks after the start of the last PDT cycle
Reported as:
Number · percentage of target lesions
Subjects' Satisfaction Regarding Esthetic Outcome and Treatment 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion or Alternative Treatment of Additional Target Lesions
percentage of target lesionsBF-200 ALAVehicle
Very good65.556.0
Good22.618.0
Satisfactory10.78.0
Unsatisfactory0.610.0
No answer0.68.0

Adverse events

Collected over The collection of adverse events (AEs) started with the subjects' informed consent (≤ 4 weeks prior to the first PDT) until the end of the clinical observation period (12 weeks after start of last PDT cycle).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BF-200 ALA0/145 (0%)3/145 (2.1%)145/145 (100%)
Vehicle0/42 (0%)2/42 (4.8%)35/42 (83.3%)
Most frequent serious events
Most frequent serious events
EventBF-200 ALAVehicle
SepsisInfections and infestations0/1451/42
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1451/42
Sinus node dysfunctionCardiac disorders1/1450/42
Atypical pneumoniaInfections and infestations1/1450/42
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1450/42
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBF-200 ALAVehicle
Application site painGeneral disorders138/14512/42
Application site erythemaGeneral disorders100/14516/42
Application site pruritusGeneral disorders73/14511/42
Application site oedemaGeneral disorders42/1455/42
Application site paraesthesiaGeneral disorders35/1455/42
Application site scabGeneral disorders32/1452/42
Application site exfoliationGeneral disorders25/1457/42
Application site indurationGeneral disorders25/1453/42
Actinic keratosisSkin and subcutaneous tissue disorders10/1455/42
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/1454/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BF-200 ALAVehicleTotal
<=18 years000
Between 18 and 65 years811596
>=65 years642791
Age, Continuous
Age, Continuous(years)BF-200 ALAVehicleTotal
Mean62.4 ± 10.866.1 ± 9.863.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)BF-200 ALAVehicleTotal
Female671178
Male7831109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BF-200 ALAVehicleTotal
Hispanic or Latino303
Not Hispanic or Latino14242184
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BF-200 ALAVehicleTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White14542187
More than one race000
Unknown or Not Reported000
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)BF-200 ALAVehicleTotal
I - III13840178
IV - VI729
Number of target lesions
Number of target lesions(Participants)BF-200 ALAVehicleTotal
1 target lesion12234156
more than 1 target lesion23831
08

Study locations

18 sites
09

References and documents

Publications

  • Schlesinger T, Chapman MS, Tu JH, Cohen JL, Strasswimmer J, Zeitouni NC, Torres A, Jazayeri SS, Goldman MP, Ibrahim SF, Lain EL, Couvillion MP, Bruce S, Laquer VT, Hanke CW, Ozog DM, Schneider J, Markowitz O, Berman B, Nestor MS, Gold MH, Munavalli GS, Forsha DW, Siegel DM, Mrohs D, Schmitz B, Schaning R, Pospiech N, Lyons J, Foguet M, Lubbert M, Lubbert H, Pariser DM. Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study. J Am Acad Dermatol. 2025 Dec;93(6):1489-1498. doi: 10.1016/j.jaad.2025.08.031. Epub 2025 Aug 20. PubMed 40846240 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Mar 2024, 65 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2018
First posted
Jun 29, 2018
StartActual
Sep 25, 2018
Primary completionActual
Mar 19, 2024
CompletionEst.
Feb 2029
Results first posted
Apr 29, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03573401
Lead sponsor
Biofrontera Inc.
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Sep 25, 2018
Primary completion
Mar 19, 2024
Completion
Feb 2029 (estimated)
Results posted
Apr 29, 2025
Last update
Jan 14, 2026

Study contacts

David M. Pariser, MD
principal investigator · Virginia Clinical Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion